Skip to main content
Clinical Trials/ACTRN12615001009505
ACTRN12615001009505
Recruiting
Phase 4

In patients having dental extractions, is continuing new oral anticoagulants (NOACs) as safe as continuing warfarin in terms of bleeding amount?

Dr Jennifer Curnow0 sites400 target enrollmentSeptember 28, 2015

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Jennifer Curnow
Enrollment
400
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 28, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dr Jennifer Curnow

Eligibility Criteria

Inclusion Criteria

  • 1\. Requires simple or surgical dental extraction(s).
  • 2\. On therapeutic dose of dabigatran, rivaroxaban, apixaban or warfarin.
  • 3\. Able to give informed consent.
  • 4\. Age 18 or above.

Exclusion Criteria

  • 1\. Women who are pregnant.
  • 2\. Concomitant use of dual anti\-platelet therapy.
  • 3\. Inherited disorder of haemostasis.
  • 4\. Platelet count \< 50 x 10^9/L.
  • 5\. Procedure for which operator requires OAC interruption.
  • 6\. OAC already ceased prior to procedure.
  • 7\. Patient on warfarin and INR \< 2 or \> 4\.
  • 8\. Severe active oral infection associated with facial swelling.
  • 9\. Cockroft\-Gaultcreatinine clearance \< 25 ml/min for patients on dabigatran, \< 30 ml/min for patients on rivaroxaban or apixaban.
  • 11\. Surgical extraction of wisdom teeth.

Outcomes

Primary Outcomes

Not specified

Similar Trials